CA1266236A - Composition cardiovasculaire - Google Patents

Composition cardiovasculaire

Info

Publication number: CA1266236A
Authority: CA; Canada
Prior art keywords: powder; psms; ethanol; ophiopogonin; aqueous
Prior art date: 1986-04-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000508064A

Other languages

English (en)

Inventor

Ya-Guang Liu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-04-30

Filing date

1986-04-30

Publication date

1990-02-27

1986-04-30 Application filed by Individual filed Critical Individual

1986-04-30 Priority to CA000508064A priority Critical patent/CA1266236A/fr

1990-02-27 Application granted granted Critical

1990-02-27 Publication of CA1266236A publication Critical patent/CA1266236A/fr

Status Expired legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 14
230000002526 effect on cardiovascular system Effects 0.000 title description 3
WLNGPDPILFYWKF-OAHLLOKOSA-N (-)-beta-chamigrene Chemical compound C1CC(C)=CC[C@]21C(C)(C)CCCC2=C WLNGPDPILFYWKF-OAHLLOKOSA-N 0.000 claims abstract description 11
MZOWOHKNFKJFFD-RRFJBIMHSA-N Sesquicarene Chemical compound C1CC(C)=C[C@H]2[C@@](CCC=C(C)C)(C)[C@H]21 MZOWOHKNFKJFFD-RRFJBIMHSA-N 0.000 claims abstract description 11
229930190017 ophiopogonin Natural products 0.000 claims abstract description 11
BDOIVSNOYYRVKL-UHFFFAOYSA-N 12(11-10)-Abeo-4-bromo-3-chloro-7,8-epxoy-11(13)-chamigren-l-ol Natural products C=C1C(C)CC2OC2(C)C21CC(Br)C(C)(Cl)CC2O BDOIVSNOYYRVKL-UHFFFAOYSA-N 0.000 claims abstract description 9
229930002306 chamigrene Natural products 0.000 claims abstract description 9
229940089161 ginsenoside Drugs 0.000 claims abstract description 7
229930182494 ginsenoside Natural products 0.000 claims abstract description 7
MZOWOHKNFKJFFD-UHFFFAOYSA-N rac-Sesquicaren Natural products C1CC(C)=CC2C(CCC=C(C)C)(C)C21 MZOWOHKNFKJFFD-UHFFFAOYSA-N 0.000 claims abstract description 6
229930013921 sesquicarene Natural products 0.000 claims abstract description 6
208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 5
230000036737 immune function Effects 0.000 claims abstract description 4
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
230000002265 prevention Effects 0.000 claims abstract description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
239000000843 powder Substances 0.000 claims description 15
238000000034 method Methods 0.000 claims description 12
230000008569 process Effects 0.000 claims description 9
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 4
241001448424 Ophiopogon Species 0.000 claims description 3
229930195210 Ophiopogon Natural products 0.000 claims description 3
244000184734 Pyrus japonica Species 0.000 claims description 2
240000006079 Schisandra chinensis Species 0.000 claims description 2
235000008422 Schisandra chinensis Nutrition 0.000 claims description 2
239000003208 petroleum Substances 0.000 claims description 2
239000000469 ethanolic extract Substances 0.000 claims 3
238000010992 reflux Methods 0.000 claims 2
238000001704 evaporation Methods 0.000 claims 1
238000002791 soaking Methods 0.000 claims 1
210000004027 cell Anatomy 0.000 description 18
230000002107 myocardial effect Effects 0.000 description 7
235000016709 nutrition Nutrition 0.000 description 7
230000035764 nutrition Effects 0.000 description 7
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000008103 glucose Substances 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
238000002372 labelling Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
210000003855 cell nucleus Anatomy 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
FHKHGNFKBPFJCB-UHFFFAOYSA-N (25S)-ruscogenin 1-O-<alpha-L-rhamnopyranosyl(1->2)><beta-D-xylopyranosyl(1->3)>-beta-D-fucopyranoside Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C45C)C)C1CC2C3CC=C4CC(O)CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(C)C(O)C1OC1OCC(O)C(O)C1O FHKHGNFKBPFJCB-UHFFFAOYSA-N 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
101150104791 MYOC gene Proteins 0.000 description 2
HGHDGOQXDUNVGT-UHFFFAOYSA-N Ophiopogonin B Natural products CC1CCC2(OC1)OC3CC4C5CC=C6CCCC(OC7OC(C)C(O)C(O)C7OC8OC(C)C(O)C(O)C8O)C6(C)C5CCC4(C)C3C2C HGHDGOQXDUNVGT-UHFFFAOYSA-N 0.000 description 2
OWGURJWJHWYCIQ-AKYREZHBSA-N Ophiopogonin B Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1O[C@@H]1C[C@H](O)CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O OWGURJWJHWYCIQ-AKYREZHBSA-N 0.000 description 2
FHKHGNFKBPFJCB-LYLKFOBISA-N Ophiopogonin D Chemical compound O([C@H]1[C@@H](O)[C@@H](C)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1C[C@H](O)CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O FHKHGNFKBPFJCB-LYLKFOBISA-N 0.000 description 2
240000004371 Panax ginseng Species 0.000 description 2
235000003140 Panax quinquefolius Nutrition 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000008434 ginseng Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
IDGCVTONMQMXPU-JHZREZMDSA-N ophiopogonin D Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@@H](O)C[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O)[C@]6(C)[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C IDGCVTONMQMXPU-JHZREZMDSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
241000408452 Acrosathe Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 1
235000002789 Panax ginseng Nutrition 0.000 description 1
235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
240000005373 Panax quinquefolius Species 0.000 description 1
241001237728 Precis Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000035584 blastogenesis Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125890 compound Ia Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
-1 hyl ether Chemical compound 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000508064A 1986-04-30 1986-04-30 Composition cardiovasculaire Expired CA1266236A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000508064A CA1266236A (fr)	1986-04-30	1986-04-30	Composition cardiovasculaire

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000508064A CA1266236A (fr)	1986-04-30	1986-04-30	Composition cardiovasculaire

Publications (1)

Publication Number	Publication Date
CA1266236A true CA1266236A (fr)	1990-02-27

Family

ID=4133014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000508064A Expired CA1266236A (fr)	1986-04-30	1986-04-30	Composition cardiovasculaire

Country Status (1)

Country	Link
CA (1)	CA1266236A (fr)

1986
- 1986-04-30 CA CA000508064A patent/CA1266236A/fr not_active Expired

Legal Events

Date	Code	Title	Description
1993-08-31	MKLA	Lapsed

Publication	Publication Date	Title
US7087252B2 (en)	2006-08-08	Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, Cistanche tubulosa (Schrenk.) Wight, process of making the same, and uses of the same
EP0200169B1 (fr)	1991-12-11	Composition pharmaceutique pour la guérison et prévention des maladies cardiovasculaires et sa méthode de préparation
DE102008039271A1 (de)	2009-06-25	Neuer Mariendistelextrakt, Verfahren zur Herstellung und Verwendung
CN113041193A (zh)	2021-06-29	一种抗刺激组合物及其制备方法和应用
DE2900887A1 (de)	1980-01-24	Verfahren zur gewinnung einer natuerlichen polarfraktion mit antipsoriatischer wirksamkeit
DE69718156T2 (de)	2003-11-06	Polypflanzliche pharmazeutische Zusammensetzungen geeignet in der Behandlung der Hepatitis E und Hepatitis B Virus-Infektion zusammenhängenden Zustände
US4944946A (en)	1990-07-31	Pharmaceutical composition for inhibiting viruses and increasing immune function (PII)
CN112791137A (zh)	2021-05-14	三种五味子提取物及其制备工艺和应用
CN101313939A (zh)	2008-12-03	岩黄连总生物碱及其制备方法与用途
AT502717A1 (de)	2007-05-15	Pharmazeutische verwendung einer verbindung
CN103263452B (zh)	2014-10-22	人面子叶乙酸乙酯提取物在制备治疗乙型病毒性肝炎药物中的应用
Ahmed et al.	1949	A contribution to the chemistry and toxicology of the root of Pbytolacca americana, L.
CN115844773B (zh)	2025-03-04	一种茯苓提取物及其制备方法和应用
EP0197525A2 (fr)	1986-10-15	Culture de cellule de plante et son utilisation
EP1395270B1 (fr)	2014-07-23	Utilisation d'éléments de phyllanthus pour la préparation d'un médicament pour la prévention ou le traitement d'une infection par le virus de l'hepatite b résistant
US4985247A (en)	1991-01-15	Pharmaceutical composition for inhibiting viruses and increasing immune function (PII)
CA1153696A (fr)	1983-09-13	Extrait de plantes du genre epimedium sp, procede de preparation agent immunostimulants contenant ledit extrait et immunotherapie effectuee avec ledit extrait
EP1498131B1 (fr)	2014-03-19	Préparation pharmaceutique contenant des glycosides phényléthanoides extraites de Cistanche tubulosa
WO2009074065A1 (fr)	2009-06-18	Utilisation de daphné primeverosyl genkwanine et de plantes de daphné
JPH0637377B2 (ja)	1994-05-18	化粧料
CN1580043B (zh)	2010-05-12	抗恶性肿瘤南柴胡萃取物的制备方法
CN112618661A (zh)	2021-04-09	一种抗病毒中药组合物及其制备方法与应用
CN112250655A (zh)	2021-01-22	两种新的环状二苯基庚烷类化合物及其制备方法和用途
CN1989984A (zh)	2007-07-04	川芎有效组分、制备方法及其制剂与用途
RU2727931C1 (ru)	2020-07-27	Средство, обладающее гепатопротективным действием